🇺🇸 FDA

Drug profile · INN

ezetimibe

EZETIMIBE AND SIMVASTATIN

approved
US status
approved
Patents linked
4
News articles
0

Quick answer

ezetimibe (EZETIMIBE AND SIMVASTATIN) is an FDA-listed pharmaceutical active ingredient. Associated with Amneal Pharma Europe Ltd. Route of administration: oral. Current US regulatory status: approved.

Key facts

INN ezetimibe
Brand EZETIMIBE AND SIMVASTATIN
Route ORAL
Formulation TABLET
Originator Amneal Pharma Europe Ltd

Related patents

Search patents →

  1. US 11744816

    Fixed dose combinations and formulations comprising ETC1002 and ezetimibe and methods of treating or reducing the risk of cardiovascular disease

    Expires Mon Aug 31 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 10912751

    Fixed dose combinations and formulations comprising ETC1002 and ezetimibe and methods of treating or reducing the risk of cardiovascular disease

    Expires Mon Feb 04 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 10905736

    Ezetimibe-associated ApoA-I mimetic peptides showing enhanced synergism

    Expires Mon Jan 28 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 9095515

    Ezetimibe compositions

    Expires Mon Jul 30 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

What is ezetimibe?

ezetimibe (EZETIMIBE AND SIMVASTATIN) is an FDA-listed pharmaceutical active ingredient. Associated with Amneal Pharma Europe Ltd. Route of administration: oral. Current US regulatory status: approved.

What is the brand name for ezetimibe?

EZETIMIBE AND SIMVASTATIN is a marketed brand name for ezetimibe. Check FDA Drugs@FDA for the current US label holder and prescribing information.

What is the US approval status of ezetimibe?

ezetimibe has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.